Radient Pharmaceuticals (RPC) Tops Q4 EPS by 26c

Radient Pharmaceuticals (NYSE: RPC) reported Q4 EPS of $0.26. Revenue for the quarter came in at $81 million.

For earnings history and earnings-related data on Radient Pharmaceuticals (RPC) click here.

You May Also Be Interested In

• MainStreet Bancshares, Inc. (MNSB) Tops Q2 EPS by 5c
• Instacart (CART) PT Raised to $56 at Cantor Fitzgerald on Compelling Risk/Reward
• Morgan Stanley (MS) PT Raised to $243 at RBC Capital After 'Another Very Strong Quarter'